12-15 Molecular Diagnostics
12-15 Molecular Diagnostics is an early-stage biotechnology company dedicated to revolutionizing testing and diagnostics with faster, more accurate, and affordable solutions. Their Veralize platform enables early detection of infections and chemical contaminants in fluids, including water, blood, saliva, and more, with results within 10 minutes. The company aims to improve public health, water quality, biodefense, and early disease detection through innovative nanotechnology and partnerships.
Industries
Nr. of Employees
small (1-50)
12-15 Molecular Diagnostics
37 Panagrossi St, Suite L, East Haven, CT 06512
Patents
Products
Portable nanotube‑based point‑of‑care diagnostic system
A portable diagnostic device using carbon‑nanotube sensor matrices encoded with sequence‑specific probes to detect pathogens or chemical contaminants in small fluid samples (saliva or water), providing results in under ~10 minutes.
Portable nanotube‑based point‑of‑care diagnostic system
A portable diagnostic device using carbon‑nanotube sensor matrices encoded with sequence‑specific probes to detect pathogens or chemical contaminants in small fluid samples (saliva or water), providing results in under ~10 minutes.
Services
Partnerships with EPA‑approved laboratories to validate water contaminant detection methods and support pathways to EPA approval.
Provision and support of portable saliva‑based diagnostic systems intended for pharmacies, doctor offices, walk‑in clinics and pre‑operative screening.
Partnerships with EPA‑approved laboratories to validate water contaminant detection methods and support pathways to EPA approval.
Provision and support of portable saliva‑based diagnostic systems intended for pharmacies, doctor offices, walk‑in clinics and pre‑operative screening.
Expertise Areas
- Point-of-care diagnostics
- Nanomaterials-based biosensor development
- Nucleic acid hybridization assays
- Water quality contaminant testing
Key Technologies
- Graphene / carbon nanotube sensor matrices
- Single‑stranded DNA/RNA hybridization assays
- Saliva‑based molecular diagnostics
- Portable point‑of‑care diagnostic hardware
News & Updates
Demonstrated 98% accuracy in NY/CT clinical trials for COVID-19
Our COVID-19 saliva test was part of a study funded by the NIH, showing high accuracy and rapid results.
Demonstrated 98% accuracy in NY/CT clinical trials for COVID-19
Our COVID-19 saliva test was part of a study funded by the NIH, showing high accuracy and rapid results.